New drug treatments show neuroprotective effects in Alzheimer’s and Parkinson’s diseases

Neural Regeneration Research

Volumn 9, Issue 21, 2014, Pages 1870-1873

  Hölscher, Christian ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Amyloid; Growth factor; Memory; Neurodegeneration; Neuroprotection; Neurotrophic factors

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; AVAGACESTAT; CRENEZUMAB; EXENDIN 4; FLUORODEOXYGLUCOSE F 18; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH FACTOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LEPTIN; NEW DRUG; SEMAGACESTAT; TARENFLURBIL; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; BLOOD BRAIN BARRIER; DESENSITIZATION; DIABETES MELLITUS; HUMAN; IMMUNE RESPONSE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

EID: 84916631997     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.145342     Document Type: Review

References (51)

1. Armstrong RA (2014) A critical analysis of the ‘amyloid cascade hypothesis’. Folia Neuropathol 52:211-225.
2. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2013) Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 123:2730-2736.
3. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Fmedsci PE, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis 4:337-344.
4. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Ronnholm H, Wikstrom L (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J Neurosci Res 86:326-338.
5. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, Laferla FM (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106:13594-13599.
6. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Abeta oligomers. J Clin Invest 122:1339-1353.
7. Bradbury J (2005) Hope for AD with NGF gene-therapy trial. Lancet Neurol 4:335.
8. Brooks M (2013) Hunting for Next-Generation Gamma-Secretase Inhibitor. In, p http://www.medscape.com/viewarticle/807818: Med-Scape.
9. Broome JD, Wills KV, Lapchak PA, Ghetti B, Camp LL, Bayer SA (1999) Glial cell line-derived neurotrophic factor protects midbrain dopa-mine neurons from the lethal action of the weaver gene: a quantitative immunocytochemical study. Brain Res Dev Brain Res 116:1-7.
10. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819-837.
11. Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, I. T-A (2006) Therapeutic actions of insulin-like growth factor I on APP/ PS2 mice with severe brain amyloidosis. Neurobiol Aging 27:1250-1257.
12. Chertoff M, Di Paolo N, Schoeneberg A, Depino A, Ferrari C, Wurst W, Pfizenmaier K, Eisel U, Pitossi F (2011) Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor alpha in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol 227:237-251.
13. Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B (2012) Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer’s disease links numerous treatment rationales. Pharmacol Rev 64:1004-1026.
14. Clarris HJ, Nurcombe V, Small DH, Beyreuther K, Masters CL (1994) Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer’s disease from hippocampal explants. J Neurosci Res 38:248-258.
15. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A (2009) Development of a non invasive NGF-based therapy for Alzheimer’s disease. Curr Alzheimer Res 6:158-170.
16. Craft S (2013) Therapeutic effects of long-acting intranasal insulin detemir for Alzheimer’s dementia or mild cognitive impairment. In: AAIC, pp O1-06-06. Boston.
17. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:29-38.
18. Cummings J, William Cho, Michael Ward, Michel Friesenhahn, Flavia Brunstein, Lee Honigberg, David Clayton DM, Carole Ho, Robert Paul (2014) A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer’s disease. In: AAIC, pp O4-11-06. Copenhagen.
19. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106:1971-1976.
20. Drinkut A, Tereshchenko Y, Schulz JB, Bahr M, Kugler S (2012) Efficient gene therapy for Parkinson’s disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther 20:534-543.
21. Extance A (2010) Alzheimer’s failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 9:741-751.
22. Fuller JP, Stavenhagen JB, Teeling JL (2014) New roles for Fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer’s disease. Front Neurosci 8:235.
23. Gomes S, Martins I, Fonseca AC, Oliveira CR, Resende R, Pereira CM (2014) Protective effect of leptin and ghrelin against toxicity induced by amyloid-beta oligomers in a hypothalamic cell line. J Neuroendocrinol 26:176-185.
24. Groves E (2013) Lilly voluntarily terminates phase ii study for LY2886721, a beta secretase inhibitor, being investigated as a treatment for Alzheimer’s disease. press release 1:https://investor.lilly. com/releasedetail.cfm?ReleaseID=771353.
25. Heese K, Low JW, Inoue N (2006) Nerve growth factor, neural stem cells and Alzheimer’s disease. Neurosignals 15:1-12.
26. Holscher C (2013) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 221:31-41.
27. Holscher C (2014a) The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement 10:S47-54.
28. Holscher C (2014b) Insulin, incretins and other growth factors as potential novel treatments for Alzheimer’s and Parkinson’s diseases. Biochem Soc Trans 42:593-599.
29. Hunter K, Holscher C (2012) Drugs developed to treat diabetes, lira-glutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13:33-38.
30. Inoue G, Cheatham B, Kahn CR (1996) Different pathways of postreceptor desensitization following chronic insulin treatment and in cells overexpressing constitutively active insulin receptors. J Biol Chem 271:28206-28211.
31. Kordower JH, Bjorklund A (2013) Trophic factor gene therapy for Parkinson’s disease. Mov Disord 28:96-109.
32. Kordower JH, Mufson EJ, Fox N, Martel L, Emerich DF (1997) Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Exp Neurol 145:586-591.
33. Long-Smith CM, Manning S, McClean PL, Coakley MF, O’Halloran DJ, Holscher C, O’Neill C (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer’s disease. Neuromolecular Med 15:102-114.
34. Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Espírito-Santo S, Campello-Costa P, Houzel JC, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, et al. (2013) TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s beta-amyloid oligomers in mice and monkeys. Cell Metab 18:831-843.
35. Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269.
36. Migliore MM, Ortiz R, Dye S, Campbell RB, Amiji MM, Waszczak BL (2014) Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease. Neuroscience 274:11-23
37. Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31:224-243.
38. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 15:331-337.
39. Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W (2014) Insulin resistance, neuroinflammation, and Alzheimer’s disease. Rev Neuro sci 25:509-525.
40. Perez-Gonzalez R, Antequera D, Vargas T, Spuch C, Bolos M, Carro E (2011) Leptin induces proliferation of neuronal progenitors and neuroprotection in a mouse model of Alzheimer’s disease. J Alzhei-mers Dis 24 Suppl 2:17-25.
41. Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, Jeon NL, Cotman CW (2009) beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging 39:821-833.
42. Reger MA, Watson GS, Frey WH,, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27:451-458.
43. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH,, Craft S (2008a) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13:323-331.
44. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008b) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448.
45. Schulte-Herbruggen O, Braun A, Rochlitzer S, Jockers-Scherubl MC, Hellweg R (2007) Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Curr Med Chem 14:2318-2329.
46. Sharma M, Hölscher C (2014) The neurophysiological and neuro-protective effects of leptin. JSM Alzheimer’s Dis Related Dementia 1:1009pp.
47. Talbot K, Want H-Y, Kazi H, Bennett D, Trojanowski JQ, Arnold SE (2011) The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer disease (AD) cases. In: AAIC, pp P4-441. Paris.
48. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:1316-1338.
49. Tan T, Bloom S (2013) Gut hormones as therapeutic agents in treatment of diabetes and obesity. Curr Opin Pharmacol 13:996-1001.
50. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22:246-260.
51. Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5:311-322.